Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers. 14 papers were listed this time. Here's a handful:
Benedict A, Figlin RA, Sandström P, et al. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. BJU Int. 2011 Jan 25. [Epub ahead of print] PMID: 21265994
Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Curr Med Res Opin. 2011 Jan 25. [Epub ahead of print] PMID: 21265593
Kimman ML, Dirksen CD, Voogd AC, et al. Economic evaluation of four follow-up strategies after curative treatment for breast cancer: Results of an RCT. Eur J Cancer. 2011 Jan 21. [Epub ahead of print] PMID: 21257305
Zanocco K, Heller M, Sturgeon C. Cost-effectiveness of parathyroidectomy for primary hyperparathyroidism. Endocr Pract. 2011 Jan 17:1-14. [Epub ahead of print] PMID: 21247844
Edwards SJ, Wordsworth S, Clarke MJ. Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactam. Eur J Health Econ. 2011 Jan 18. [Epub ahead of print] PMID: 21243514
